



Zeal & Innovation in Medicine

Ref No.: ZLL/CS/BSE/NSE

Date: 19.03.2025

BSE Limited, Corporate Relationship Department P. J. Towers, Dalal Street, Mumbai- 400 001 Company Code- 541400	National Stock Exchange of India Limited Listing Compliance Department Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051 (Symbol - ZIMLAB)
---	---

Dear Sir/Madam,

Sub: Press Release for grant of Marketing Authorization for Dimethyl Fumarate 120 mg & 240 mg Modified Release Capsules in Portugal, Europe

Please find enclosed herewith our Press Release relating to grant of Marketing Authorization for “Dimethyl Fumarate 120 mg & 240 mg Modified Release Capsules” in Portugal, Europe to the Wholly owned European Subsidiary of the Company.

Request you to kindly take the same on your record.

Thanking you,

Yours faithfully,
For ZIM LABORATORIES LIMITED

(Piyush Nikhade)
Company Secretary and Compliance Officer
Membership No. A38972

Encl : As Above

ZIM LABORATORIES LIMITED

www.zimlab.in | info@zimlab.in | CIN : L99999MH1984PLC032172

Works : B-21/22, MIDC Area, Kalmeshwar – 441 501 Dist. Nagpur
Maharashtra, India. Ph. + 91.718.271370 | Fax : +091.7118.271470

Regd. Office : Sadoday Gyan (Ground Floor), Opp. NADT, Nelson Square,
Nagpur – 440013. Maharashtra, India. Ph. +091.712.2981960

PRESS RELEASE

ZIM Laboratories Limited
Receives Marketing Authorization (MA) for
Dimethyl Fumarate (120 mg & 240 mg) Modified Release Capsules
in Portugal, Europe

Nagpur, India March 19, 2025:

About ZIM Laboratories Limited

ZIM Laboratories Limited (the Company) is a research-driven Pharmaceutical company that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms across key therapeutic segments. The Company has state-of-the-art in-house R&D capabilities to offer innovative drug delivery solutions using proprietary technology platforms, aiming to enhance patient convenience and treatment adherence. ZIM Laboratories Limited is listed on the National Stock Exchange of India Limited (NSE) and BSE Limited.

The Company is pleased to announce today that INFARMED (Portugal) – the Portuguese National Authority of Medicines and Health Products – has granted Marketing Authorization (MA) for ZIM's Central Nervous System (CNS) product "Dimethyl Fumarate 120 mg & 240 mg Modified Release Capsules," in Portugal to its wholly owned European subsidiary, SIA ZIM Laboratories Limited.

This authorisation will facilitate faster approvals in other European Union countries as well as the UK and other markets globally resulting in better commercialisation opportunities.

Dimethyl Fumarate Modified Release Capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS) and are developed using ZIM's proprietary technology and is bioequivalent to the Innovator's product.

According to IQVIA, the EU market size for this product in 2023 was approximately USD 800 MN while UK contributed 200 MN USD. Other markets (Ex USA & Japan) contributed 42 MN USD.